The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over, the U.S. Food and Drug ...
Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...
Indianapolis-based Eli Lilly’s supply of Mounjaro, which is used to treat Type 2 diabetes, and popular weight-loss drug ...
"God knows what volume they're actually selling. And who knows? You're just taking it," one expert told The Post.
The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making ...
DSM-Firmenich's new sunscreen ingredient bemotrizinol (PARSOL Shield) is under FDA review; if approved, it would be the first ...
Food left in the stomach or stool left in the bowel can impede a doctor's ability to successfully perform an endoscopy or ...
In Q2, it brought in $11.3 billion in sales, 36% higher than a year prior, and it cranked up its annual revenue guidance for ...
About 40% of U.S. adults suffer from obesity, and the cost of covering GLP-1 agonists and related anti-obesity drugs can be ...
Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...
The executive led the diet company, better known as WeightWatchers, since 2022 into the burgeoning market for obesity drugs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback